AYTU - Aytu BioScience Inc Stock Price, Fair Value and News

3.10USD+0.04 (+1.31%)Market Closed

Market Summary

USD3.10+0.04

Market Closed

1.31%

AYTU Stock Price

View Fullscreen

AYTU RSI Chart

AYTU Valuation

Market Cap

17.0M

Price/Earnings (Trailing)

-0.95

Price/Sales (Trailing)

0.17

EV/EBITDA

-2.78

Price/Free Cashflow

2.78

AYTU Price/Sales (Trailing)

AYTU Profitability

Operating Margin

59.54%

EBT Margin

-17.43%

Return on Equity

-54.78%

Return on Assets

-13.71%

Free Cashflow Yield

35.95%

AYTU Fundamentals

AYTU Revenue

Revenue (TTM)

98.5M

Rev. Growth (Yr)

-12.73%

Rev. Growth (Qtr)

3.78%

AYTU Earnings

Earnings (TTM)

-18.0M

Earnings Growth (Yr)

96.71%

Earnings Growth (Qtr)

97.29%

Breaking Down AYTU Revenue

Last 7 days

8.5%

Last 30 days

-5.3%

Last 90 days

20.5%

Trailing 12 Months

73.3%

How does AYTU drawdown profile look like?

AYTU Financial Health

Current Ratio

1.11

Debt/Equity

0.46

Debt/Cashflow

0.41

AYTU Investor Care

Shares Dilution (1Y)

55.81%

Diluted EPS (TTM)

-6.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	104.1M	107.4M	101.8M	98.5M
2022	92.7M	96.7M	102.4M	105.6M
2021	57.0M	65.6M	74.0M	82.0M
2020	14.5M	27.6M	39.7M	51.7M
2019	6.5M	7.3M	7.3M	8.7M
2018	3.6M	3.7M	4.0M	4.8M
2017	3.3M	3.3M	3.3M	3.4M
2016	1.8M	2.6M	2.8M	3.1M
2015	110.2K	261.8K	721.6K	1.2M
2014	31.7K	45.3K	76.7K	92.5K
2013	33.6K	41.8K	18.1K	0
2012	0	0	17.2K	25.4K
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aytu BioScience Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	pyszczymuka greg	acquired	-	-	208	chief commercial officer
Dec 31, 2023	pyszczymuka greg	acquired	-	-	209	chief commercial officer
Sep 30, 2023	pyszczymuka greg	acquired	-	-	208	chief commercial officer
Aug 16, 2023	jain abhinav	acquired	-	-	6,500	-
Aug 11, 2023	liu vivian h	acquired	-	-	1,500	-
Aug 11, 2023	jain abhinav	acquired	-	-	1,500	-
Aug 11, 2023	dockery carl	acquired	-	-	1,500	-
Aug 11, 2023	donofrio john jr.	acquired	-	-	1,500	-
Jun 30, 2023	pyszczymuka greg	acquired	-	-	208	chief commerical officer
Jun 16, 2023	pyszczymuka greg	bought	22,428	1.869	12,000	chief commerical officer

Which funds bought or sold AYTU recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 03, 2024	HUNTINGTON NATIONAL BANK	new	-	61.00	61.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 16, 2024	TSFG, LLC	unchanged	-	-	-	-%
Apr 11, 2024	West Financial Advisors, LLC	new	-	31.00	31.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	110	42,366	77,393	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	78,850	78,850	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	100	3,238,700	6,173,090	0.18%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	5.00	105	-%
Feb 14, 2024	Royal Bank of Canada	added	2,283	10,000	10,000	-%

Are Funds Buying or Selling AYTU?

Are funds buying AYTU calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AYTU

No. of Funds

Unveiling Aytu BioScience Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	stonepine capital management, llc	9.99%	565,484	SC 13G/A
Jun 16, 2023	stonepine capital management, llc	9.99%	563,842	SC 13G
Jun 16, 2023	nantahala capital management, llc	19.7%	1,086,812	SC 13D/A
May 26, 2023	nantahala capital management, llc	7.2%	271,595	SC 13D
Feb 14, 2023	cvi investments, inc.	4.9%	3,278,844	SC 13G/A
Aug 15, 2022	cvi investments, inc.	5.6%	3,400,000	SC 13G
Feb 11, 2022	stonepine capital management, llc	0%	0	SC 13G/A
Sep 01, 2021	armistice capital, llc	4.9%	-	SC 13D/A
Aug 31, 2021	armistice capital, llc	5.3%	-	SC 13D/A
Mar 26, 2021	integrated core strategies (us) llc	0.0%	2,446	SC 13G

Recent SEC filings of Aytu BioScience Inc

View All Filings

Date Filed	Form Type	Document
Apr 02, 2024	4	Insider Trading
Feb 14, 2024	8-K	Current Report
Feb 14, 2024	10-Q	Quarterly Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Aytu BioScience Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Aytu BioScience Inc News

Latest updates

Aytu BioScience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.8%	22,934	22,099	30,732	22,733	26,279	27,655	27,448	24,199	23,125	21,897	23,482	13,483	15,147	13,520	14,861	8,156	3,175	1,440	1,716	2,378	1,795
Cost Of Revenue	-	-	-	-	9,990	8,986	9,623	12,606	11,513	10,826	9,441	12,183	13,935	6,251	4,063	5,301	1,999	606	376	649	617	525
Gross Profit	9.6%	16,203	14,784	18,564	12,743	17,293	18,032	14,842	12,686	12,299	12,456	11,299	-452	8,896	9,457	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	39,148	20,722	-	-	12,950	8,142	-	-	-	-
Operating Expenses	-15.0%	13,839	16,288	18,395	21,301	24,161	19,840	32,058	66,107	23,593	40,155	35,371	25,214	14,471	13,014	13,215	12,950	8,142	6,175	6,296	6,676	6,346
S&GA Expenses	-11.4%	6,576	7,422	7,982	12,804	10,560	10,102	10,013	9,743	9,660	9,297	12,180	6,597	5,705	5,826	-8,770	9,190	6,516	5,146	4,896	5,369	5,046
R&D Expenses	-13.2%	524	604	465	856	1,710	1,064	3,253	3,282	4,475	1,652	4,764	390	286	183	1,499	79.00	67.00	78.00	175	109	149
EBITDA Margin	58.2%	-0.05*	-0.11*	-0.04*	-0.18*	-0.61*	-0.68*	-0.99*	-1.04*	-0.85*	-0.93*	-0.72*	-0.09*	-0.10*	-	-	-	-	-	-	-	-
Interest Expenses	-40.3%	811	1,359	951	840	1,456	565	68.00	724	668	1,688	800	142	59.00	248	253	539	447	195	137	195	128
Income Taxes	-	828	-	-	-	-	-	-	-	-3.00	-107	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	107.5%	608	-8,120	-2,457	-7,200	-6,693	-701	-16,089	-53,291	-11,551	-27,958	-18,739	-25,460	-9,525	-4,306	-	-	-	-	-	-	-
EBT Margin	27.5%	-0.17*	-0.24*	-0.16*	-0.29*	-0.73*	-0.80*	-1.13*	-1.20*	-1.02*	-1.10*	-0.88*	-0.24*	-0.26*	-	-	-	-	-	-	-	-
Net Income	97.3%	-220	-8,120	-2,457	-7,200	-6,693	-701	-16,089	-53,291	-11,548	-27,851	-18,998	-25,460	-9,525	-4,306	-3,145	-5,332	-214	-4,929	-14,531	-4,495	-4,657
Net Income Margin	24.0%	-0.18*	-0.24*	-0.16*	-0.29*	-0.73*	-0.80*	-1.13*	-1.20*	-1.02*	-1.11*	-0.89*	-0.74*	-0.43*	-	-	-	-	-	-	-	-
Free Cashflow	36.0%	-135	-211	15,221	2,938	3,362	-3,250	-1,245	-3,265	-2,972	2,059	-450	25,550	2,926	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.2%	131	133	136	147	141	150	138	169	224	228	266	272	167	141	153	159	74.00	31.00	35.00	38.00	42.00
Current Assets	1.1%	71.00	71.00	73.00	78.00	71.00	74.00	60.00	78.00	88.00	89.00	105	100	93.00	65.00	75.00	83.00	18.00	12.00	15.00	18.00	22.00
Cash Equivalents	-2.2%	20.00	20.00	23.00	19.00	20.00	24.00	19.00	28.00	35.00	40.00	50.00	47.00	62.00	38.00	48.00	62.00	5.00	7.00	11.00	15.00	18.00
Inventory	0.3%	13.00	13.00	12.00	14.00	13.00	13.00	11.00	14.00	17.00	16.00	16.00	17.00	7.00	11.00	10.00	4.00	2.00	1.00	1.00	2.00	2.00
Net PPE	-	1.00	-	2.00	-	-	-	-	-	-	-	-	6.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	-	9.00	46.00	46.00	66.00	38.00	28.00	28.00	28.00	24.00	15.00	-	-	-	-
Liabilities	-100.0%	-	101	97.00	106	96.00	102	93.00	108	118	116	128	128	54.00	50.00	58.00	73.00	57.00	29.00	28.00	22.00	23.00
Current Liabilities	-1.9%	64.00	65.00	69.00	85.00	67.00	73.00	64.00	80.00	101	98.00	109	84.00	26.00	22.00	29.00	42.00	16.00	6.00	5.00	5.00	5.00
Short Term Borrowings	-15.6%	1.00	1.00	2.00	10.00	7.00	-	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	0.9%	15.00	15.00	15.00	11.00	15.00	14.00	14.00	14.00	0.00	0.00	0.00	-	-	-	-	8.00	23.00	-	-	5.00	5.00
LT Debt, Current	-	0.00	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	15.00	-	15.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	2.1%	33.00	32.00	39.00	41.00	46.00	48.00	44.00	58.00	106	112	138	143	113	91.00	95.00	86.00	17.00	2.00	7.00	16.00	20.00
Retained Earnings	-0.1%	-312	-312	-304	-301	-294	-287	-287	-270	-217	-206	-178	-159	-133	-124	-120	-116	-111	-111	-106	-91.86	-87.36
Additional Paid-In Capital	0.3%	345	344	343	343	340	336	331	329	323	318	316	302	247	215	215	203	129	114	113	108	107
Shares Outstanding	0.7%	6.00	6.00	6.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	12.00	-	-	-	38.00	-	-	-	88.00	-	-	-	10.00	-	-	-	7.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	36.0%	-135	-211	9,365	-2,894	-2,452	-9,148	-7,072	-9,115	-8,822	-3,791	-6,277	19,700	-2,917	-7,983	-7,764	20,600	-6,099	-2,987	-3,473	-3,310	-4,302
Share Based Compensation	-11.8%	820	930	900	902	3,067	1,177	1,230	1,270	1,229	1,519	1,089	1,522	508	455	488	263	162	165	299	377	194
Cashflow From Investing	-128.9%	-174	-76.00	-155	1.00	-5.00	42.00	-41.00	-70.00	-3,051	-86.00	-2,426	-317	-30.00	-9.00	-45.27	344	-4,912	-1,042	-96.11	-105	-557
Cashflow From Financing	95.4%	-126	-2,734	-5,404	2,583	-1,865	13,557	-1,117	1,521	6,590	-5,464	11,814	-6,398	27,076	-2,178	-6,372	68,183	9,258	-	117	259	18,700

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AYTU Income Statement

2023-12-31

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Product revenue, net	$ 22,934	$ 26,279	$ 45,033	$ 53,934
Cost of sales	6,731	8,986	14,046	18,609
Gross profit	16,203	17,293	30,987	35,325
Operating expenses:
Selling and marketing	6,576	10,560	13,998	20,662
General and administrative	5,439	8,018	12,395	15,340
Research and development	524	1,710	1,128	2,774
Amortization of intangible assets	1,300	1,198	2,606	2,395
Impairment expense	0	2,600	0	2,600
Loss from contingent consideration	0	75	0	230
Total operating expenses	13,839	24,161	30,127	44,001
Income (loss) from operations	2,364	(6,868)	860	(8,676)
Other expense, net	(1,179)	(1,228)	(1,888)	(2,312)
(Loss) gain on derivative warrant liabilities	(577)	1,403	(6,484)	3,594
Income (loss) before income tax	608	(6,693)	(7,512)	(7,394)
Income tax expense	828	0	828	0
Net loss	$ (220)	$ (6,693)	$ (8,340)	$ (7,394)
Basic and diluted weighted-average common shares outstanding (in shares)	5,517,670	3,110,304	5,499,951	2,817,979
Basic and diluted net loss per common share (in dollars per share)	$ (0.04)	$ (2.15)	$ (1.52)	$ (2.62)

AYTU Balance Sheet

2023-12-31

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands

Dec. 31, 2023

Jun. 30, 2023

Current assets:

Cash and cash equivalents

$ 19,529

$ 22,985

Accounts receivable, net

29,403

28,937

Inventories

13,001

11,995

Prepaid expenses

8,105

8,047

Other current assets

1,333

868

Total current assets

71,371

72,832

Non-current assets:

Property and equipment, net

1,127

1,815

Operating lease right-of-use assets

^[1]

2,133

2,054

Intangible assets, net

55,711

58,970

Other non-current assets

907

792

Total non-current assets

59,878

63,631

Total assets

131,249

136,463

Current liabilities:

Accounts payable

10,473

13,478

Accrued liabilities

43,413

46,799

Short-term line of credit

1,026

1,563

Current portion of debt

Other current liabilities

9,236

7,090

Total current liabilities

64,187

69,015

Non-current liabilities:

Debt, net of current portion

14,978

14,713

Derivative warrant liabilities

12,887

6,403

Other non-current liabilities

6,344

6,975

Total non-current liabilities

34,209

28,091

Commitments and contingencies (note 13)

Stockholders’ equity:

Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding

Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,347 and 5,517,174 shares issued and outstanding, respectively

Additional paid-in capital

345,321

343,485

Accumulated deficit

(312,469)

(304,129)

Total stockholders’ equity

32,853

39,357

Total liabilities and stockholders’ equity

$ 131,249

$ 136,463

[1]	Includes $0.2 million from the Consumer Health Segment as of December 31, 2023 and June 30, 2023.

About Aytu BioScience Inc

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

CEO	Mr. Joshua R. Disbrow
WEBSITE	https://aytubio.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	164

Aytu BioScience Inc Frequently Asked Questions

What is the ticker symbol for Aytu BioScience Inc? What does AYTU stand for in stocks?

AYTU is the stock ticker symbol of Aytu BioScience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aytu BioScience Inc (AYTU)?

As of Tue May 07 2024, market cap of Aytu BioScience Inc is 17.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers. The fair value of Aytu BioScience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aytu BioScience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AYTU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aytu BioScience Inc a good stock to buy?

The fair value guage provides a quick view whether AYTU is over valued or under valued. Whether Aytu BioScience Inc is cheap or expensive depends on the assumptions which impact Aytu BioScience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AYTU.

What is Aytu BioScience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, AYTU's PE ratio (Price to Earnings) is -0.95 and Price to Sales (PS) ratio is 0.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AYTU PE ratio will change depending on the future growth rate expectations of investors.